Watch out for fake Botox in the U.S.

A counterfeit version of onabotulinumtoxinA (Botox) was found in the United States and may have been sold to physicians' offices and medical clinics nationwide. This version is considered unsafe and should not be used. » Fake verses authentic Botox

Study details problems with COPD drug

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation—which possibly results in patients developing a tolerance to the drug after repeated use and renders it ineffective, according to a study. » An important finding from researchers

Continuing Education

MTM essentials for asthma: Part 1

This month Drug Topics and the University of Connecticut School of Pharmacy offer a new CPE series: MTM for the patient with respiratory disease. Pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities (released April – December 2015). This month the series kicks off with MTM essentials for asthma management, covering the pathophysiology of asthma, clinical presentations of asthma, assessment methods, and nonpharmacologic management options.

To read and print the article with TEST questions, click here

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT29-YKX36.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

New cystic fibrosis drugs may significantly increase pharmacy benefit costs

New cystic fibrosis treatments, that target the gene mutations causing the disease, will significantly increase healthcare costs, according to a study presented at the Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting and Expo, in San Diego. » Cost breakdown

• FDA updates Chantix label to include possible alcohol interaction

• [BLOG]: Best Practices between formulary managers and pharmacists to address challenges in COPD readmissions

RESOURCES

Latest Clinical News